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Pt-Mal-LHRH, a newly synthesized compound attenuating breast cancer tumor 
growth and metastasis by targeting overexpression of the LHRH receptor
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Figure 1: Pt-Mal-LHRH attenuates breast cancer cell viability. 4TI breast
cancer cells were treated with Pt-Mal-LHRH, LHRH, or Carboplatin (Carbo) from a
range of 0.1μM to 100μM. Viability rates were analyzed by a MTT assay after a
treatment incubation of 72 hours. **, p>0.01 ***. p>0.001, ****, p>0.0001
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Determine therapeutic profile of Pt-Mal-LHRH, including toxic and 
lethal dose indexes. 
 Further evaluate Pt-Mal-LHRH’s ability to attenuate metastasis.
Platinum based chemotherapy remains a current standard of cancer treatment, 
especially in aggressive late stage breast carcinomas. However, due to 
increased resistance to Cisplatin and Carboplatin, newer strategies of drug 
intervention are needed. As a result, Pt-Mal-LHRH was synthesized to 
alleviate the need for more efficacious chemotherapy.
Our current data suggests;
 Pt-Mal-LHRH attenuates breast cancer cell viability. 
 Pt-Mal-LHRH is more selective to cancer cells, resulting in greater uptake 
of drug compared to normal mammary cells.
Cancer cell migration is attenuated by Pt-Mal-LHRH
 Pt-Mal-LHRH reduces tumor size as well as attenuates lung tumor 
colonization.





Pt-Mal-LHRH Reduces Breast Cancer Cell 
Viability
Support
Pt-Mal-LHRH Reduces Tumor Size In-Vivo
For 2015, there are an estimated 1,658,370 new cancer cases
diagnosed in the United States, of which 231,840 are attributed to breast
cancer with 40,290 deaths. The individual survival rate and prognosis
depends on the type of cancer, in which, highly aggressive and invasive
carcinomas promote the most mortality. In women, breast cancer is the
forefront leading cause of all cancer among women (41%) followed by
uterine corpus (8%), and colon and rectum cancer (8%). Additionally, in the
United States, breast cancer afflicts 1 in 8 women during their lifetime, this
high prevalence provides evidence for the need to foster new therapeutic
interventional research. Despite recent advances in the first-line treatment
of breast cancer, many patients eventually relapse, their tumors become
chemoresistant, and the patients subsequently die of the disease. One of the
major problems in cancer chemotherapy is the deleterious side effects of
anticancer drugs designed to destroy rapidly dividing cells, including those
found in healthy tissues. Due to these severe side effects, doctors often
resort to dose reduction, treatment delay or discontinuance of therapy. To
combat this problem, a new approach to chemotherapy intervention was
devised by synthesizing Pt-Mal-LHRH, a Carboplatin analog which
selectively targets cancer cells.
In the United States one in eight women will be afflicted with breast
cancer. Triple negative (4T1) breast cancers account for 15% of all breast
cancers and are significantly more aggressive than other subtypes. Treatment
options for triple negative breast cancer are limited due to the cancers being
unresponsive to hormonal therapy. Our recent work revolves around
developing a novel chemotherapeutic agent that will direct therapy
selectively to 4T1 cancer cells while decreasing systemic distribution.
Others have reported an upregulation of the luteinizing hormone-releasing
hormone (LHRH) receptor on 4T1 cells. We have designed and synthesized a
Pt-Mal-LHRH compound that uses the LHRH peptide to selectively target
and deliver Platinum intracellularly to the 4T1 cells. Platinum is used in
chemotherapy in common compounds such as cisplatin and carboplatin.
Both cisplatin and carboplatin are effective chemotherapeutic agents,
however, they are not cancer specific and elicit debilitating side effects.
To address, whether Pt-Mal-LHRH is more selective and efficacious than
carboplatin we have designed in-vitro experiments to compare other
chemotherapeutic agents. First, we verified that Pt-Mal-LHRH reduces 4T1
proliferation through an MTT assay. We found that Pt-Mal-LHRH reduces
4T1 viability compared to carboplatin. Next, we found through flow
cytometry that Pt-Mal-LHRH increases 4T1 apoptosis compared to
carboplatin. In addition, we found a 20-fold increase in cellular uptake of
Pt-Mal-LHRH compared to carboplatin. Taken together we have found that
Pt-Mal-LHRH increases 4T1 cell death through increased cellular uptake.
Our future directions will decipher the molecular mechanism of action
including DNA binding rates and adduct formation.
Figure 6: Breast cancer tumor growth is attenuated by Platinum-LHRH
treatment. Female BALB/c mice were implanted with 4T1 cells (1x106) in the right
second mammary fat pad. Tumors were grown for 7 days, distributed into treatment
groups, and treated with Carboplatin (Carbo), Carboplatin and LHRH, or Platinum-
LHRH (5mg/kg/wk) by intraperitoneal injection for 2 wks. Tumor volume was
measured over the 2 wk injection period (A) along with end tumor weight (B).
Figure 4: Future Experiment. A kinetic profile will be determined for the action of
Pt-Mal-LHRH and compared to the kinetic profile of Carboplatin for similarities to
the binding of Guanine residues and subsequent DNA cross-link formation and
destruction, over a period of time.
Figure 3: Cellular uptake of Pt-Mal-LHRH is significantly greater in cancer cells. To
measure drug uptake 1x106 cells were treated with Platinum-LHRH or Carboplatin
(100μM) for 24 hours. Cells were collected and metal (platinum) concentration mg/L was
measured using ICP-MS. (n=3) ****, p>0.0001




























































Figure 5: Pt-Mal-LHRH was confirmed to be cytotoxic by flow cytometry using
a propidium iodide stain. Pt-Mal-LHRH displayed a 20-fold increase in 4T1
cellular uptake compared to carboplatin. There was a decrease (p<0.0001) in 4T1
cell viability compared to 3T3 normal fibroblast cells
Pt-Mal-LHRH is More Selective Towards Cancer 
Cells
Figure 2: Pt-Mal-LHRH attenuates 4T1 breast cancer cell viability compared
to normal mammary cells (3T3). 4T1 and 3T3 cells were treated with Pt-Mal-
LHRH from a range of 0.1μM to 100μM. Viability rates were analyzed by a MTT
assay after 72 hours of treatment. (n=3) ****,p>0.0001
